This page shows the latest Sutimlimab news and features for those working in and with pharma, biotech and healthcare.
Sutimlimab – a first-in-class selective inhibitor of complement C1s – has hit the mark in cold agglutinin disease (CAD), a rare, autoimmune form of haemolytic anaemia that causes blood clots, leading ... In the phase 3 CARDINAL study reported at the
The French drugmaker is also working on sutimlimab, an antibody for cold agglutinin disease in phase 3 testing, long-acting clotting factor BIVV001 for haemophilia A (phase 2) and gene-editing
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...